Genmab | GEN - Ebitda


Genmab reported DKK401M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Almirall EUR 114.07M 60.37M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 3.86B 1.28B Mar/2026
argenx SE USD 427M 22.88M Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
Bayer EUR 2.14B 2.31B Jun/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Demant DKK 2.8B 47M Jun/2026
Exelixis USD 255.4M 2.89M Jun/2026
Fresenius Medical Care EUR 843.66M 19.66M Jun/2026
Genmab DKK 401M 186M Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
GN Store Nord DKK 352M 139M Jun/2026
GRIFOLS EUR 473M 120M Jun/2026
Hikma Pharmaceutical USD 369M 84M Dec/2024
Insmed USD -148.3M 165.88M Mar/2026
Lakefront Biotherapeutics EUR -63.7M 624.2M Mar/2026
Lonza CHF 1.01B 54M Dec/2025
Merck EUR 1.6B 69M Jun/2026
Novartis USD 6.48B 1.19B Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
UCB EUR 1.6B 570M Dec/2025